Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 10-14 weeks | |
50 mg | $1,980 | 10-14 weeks | |
100 mg | $2,500 | 10-14 weeks |
Description | GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM. It demonstrates significant enhancement of hepatocyte glucose uptake (38%). This compound holds great potential for studying various diseases including diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder [1]. |
In vitro | GSK-3β inhibitor 6 (Compound B30, 0-30 μΜ, 30 min) demonstrates effective GSK-3β kinase inhibition (IC 50: 24.4 μM) while also significantly enhancing hepatocyte glucose uptake by 38% (5 μM, 3 h) without notable toxicity to HepG2 cells [1]. |
In vivo | GSK-3β inhibitor 6 (Compound 5k), administered orally at 20 mg/kg, demonstrates favorable pharmacokinetics, including a half-life (t 1/2) of 1.41 hours and a peak concentration (C max) of 288 ng/mL in Sprague-Dawley rats used for pharmacokinetic assessment. The study explored two administration routes: intravenous injection at 2 mg/kg and oral delivery at 20 mg/kg. The pharmacokinetic outcomes reveal that the oral administration of GSK-3β inhibitor 6 results in a half-life of 1.41 hours, time to peak concentration (Tmax) of 1.33 hours, and oral bioavailability (F) of 11.4%. In contrast, intravenous injection exhibits a slightly longer half-life of 2.13 hours and a quicker Tmax of 0.08 hours, underscoring the influence of administration routes on the compound's pharmacokinetic profile. |
Molecular Weight | 393.28 |
Formula | C20H17BrN4 |
Cas No. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.